{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:46:32Z","timestamp":1787755592089,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01566-z","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T03:04:14Z","timestamp":1753153454000},"page":"757-763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Addressing the drug development challenge for rare pediatric diseases in Japan: a case study of isotretinoin"],"prefix":"10.1007","volume":"43","author":[{"given":"Shota","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayase","family":"Hakariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan D.","family":"Florez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"1566_CR1","unstructured":"Institute of Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Development, Field MJ, Boat TF (2010) Innovation and the Orphan Drug Act, 1983\u20132009: Regulatory and Clinical Characteristics of Approved Orphan Drugs. In: Rare Diseases and Orphan Products: Accelerating Research and Development. National Academies Press (US)"},{"key":"1566_CR2","unstructured":"Ministry of Health, Labour and Welfare (2025) Overview of the designation system for orphan drugs, orphan medical devices, and orphan regenerative medical products. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000068484.html. Accessed 8 Apr 2025"},{"key":"1566_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(24)01175-9","volume":"404","author":"A Koyama","year":"2024","unstructured":"Koyama A, Ozaki A, Hori A, Tanimoto T (2024) Tackling Japan\u2019s population crisis by improving the childcare environment. Lancet 404:333\u2013334. https:\/\/doi.org\/10.1016\/S0140-6736(24)01175-9","journal-title":"Lancet"},{"key":"1566_CR4","doi-asserted-by":"publisher","DOI":"10.4161\/rdis.23579","volume":"1","author":"S Bavisetty","year":"2013","unstructured":"Bavisetty S, Grody WW, Yazdani S (2013) Emergence of pediatric rare diseases: review of present policies and opportunities for improvement: Review of present policies and opportunities for improvement. Rare Dis 1:e23579. https:\/\/doi.org\/10.4161\/rdis.23579","journal-title":"Rare Dis"},{"key":"1566_CR5","unstructured":"Ministry of Health, Labour and Welfare (2024) Overview of national medical expenses in fiscal year 2022. [in Japanese] https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/k-iryohi\/22\/dl\/kekka.pdf. Accessed 8 Apr 2025"},{"key":"1566_CR6","unstructured":"Digital Innovation City Association Digital Innovation City Association (2023) Projected future population of Japan. [in Japanese] https:\/\/www.ipss.go.jp\/pp-zenkoku\/j\/zenkoku2023\/pp2023_gaiyou.pdf. Accessed 8 Apr 2025"},{"key":"1566_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s43441-020-00218-z","volume":"55","author":"E Ueyama","year":"2021","unstructured":"Ueyama E, Kaneko M, Narukawa M (2021) Analysis of pediatric drug approval lag in Japan. Ther Innov Regul Sci 55:336\u2013345. https:\/\/doi.org\/10.1007\/s43441-020-00218-z","journal-title":"Ther Innov Regul Sci"},{"key":"1566_CR8","unstructured":"Pile HD, Sadiq NM (2025) Isotretinoin. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"1566_CR9","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu AL, Gilman AL, Ozkaynak MF et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324\u20131334. https:\/\/doi.org\/10.1056\/NEJMoa0911123","journal-title":"N Engl J Med"},{"key":"1566_CR10","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-20-3909","volume":"27","author":"AL Yu","year":"2021","unstructured":"Yu AL, Gilman AL, Ozkaynak MF et al (2021) Long-term follow-up of a phase III study of ch14.18 (dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032. Clin Cancer Res 27:2179\u20132189. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3909","journal-title":"Clin Cancer Res"},{"key":"1566_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/pbc.25501","volume":"62","author":"NS Parikh","year":"2015","unstructured":"Parikh NS, Howard SC, Chantada G et al (2015) SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low- and middle-income settings: SIOP-PODC Adapted Risk Stratification and Treatment. Pediatr Blood Cancer 62:1305\u20131316. https:\/\/doi.org\/10.1002\/pbc.25501","journal-title":"Pediatr Blood Cancer"},{"key":"1566_CR12","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","volume":"341","author":"KK Matthay","year":"1999","unstructured":"Matthay KK, Villablanca JG, Seeger RC et al (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children\u2019s Cancer Group. N Engl J Med 341:1165\u20131173. https:\/\/doi.org\/10.1056\/NEJM199910143411601","journal-title":"N Engl J Med"},{"key":"1566_CR13","unstructured":"Japan Registry of Clinical Trials (jRCT). https:\/\/jrct.mhlw.go.jp\/en-top. Accessed 23 Jun 2025"},{"key":"1566_CR14","unstructured":"Pharmaceuticals and Medical Devices Agency. [in Japanese] https:\/\/www.pmda.go.jp\/index.html. Accessed 10 Jun 2025"},{"key":"1566_CR15","unstructured":"Evaluation Committee on Unapproved or Off-label Drugs with High Medical Needs. [in Japanese] https:\/\/www.mhlw.go.jp\/stf\/shingi\/other-iyaku_128701.html. Accessed 22 Jun 2025"},{"key":"1566_CR16","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s10147-018-1281-8","volume":"23","author":"T Hishiki","year":"2018","unstructured":"Hishiki T, Matsumoto K, Ohira M et al (2018) Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). Int J Clin Oncol 23:965\u2013973. https:\/\/doi.org\/10.1007\/s10147-018-1281-8","journal-title":"Int J Clin Oncol"},{"key":"1566_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30976","volume":"71","author":"A Yoneda","year":"2024","unstructured":"Yoneda A, Shichino H, Hishiki T et al (2024) A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: the Japan Children\u2019s Cancer Group Neuroblastoma Committee Trial JN-H-11. Pediatr Blood Cancer 71:e30976. https:\/\/doi.org\/10.1002\/pbc.30976","journal-title":"Pediatr Blood Cancer"},{"key":"1566_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jcb.22094","volume":"107","author":"LM Wagner","year":"2009","unstructured":"Wagner LM, Danks MK (2009) New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem 107:46\u201357. https:\/\/doi.org\/10.1002\/jcb.22094","journal-title":"J Cell Biochem"},{"key":"1566_CR19","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1097\/mph.0000000000001684","volume":"43","author":"J Hara","year":"2021","unstructured":"Hara J, Nitani C, Kawamoto H et al (2021) A phase I\/IIa study of antidisialoganglioside antibody dinutuximab in Japanese patients with neuroblastoma. J Pediatr Hematol Oncol 43:e358\u2013e364. https:\/\/doi.org\/10.1097\/mph.0000000000001684","journal-title":"J Pediatr Hematol Oncol"},{"key":"1566_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103755","volume":"28","author":"K Enya","year":"2023","unstructured":"Enya K, Lim Y, Sengoku S, Kodama K (2023) Increasing orphan drug loss in Japan: trends and R&D strategy for rare diseases. Drug Discov Today 28:103755. https:\/\/doi.org\/10.1016\/j.drudis.2023.103755","journal-title":"Drug Discov Today"},{"key":"1566_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1297\/cpe.29.1","volume":"29","author":"H Saitou","year":"2020","unstructured":"Saitou H, Nakatani D, Myoui A et al (2020) Pediatric drug development in Japan: current issues and perspectives. Clin Pediatr Endocrinol 29:1\u20137. https:\/\/doi.org\/10.1297\/cpe.29.1","journal-title":"Clin Pediatr Endocrinol"},{"key":"1566_CR22","unstructured":"Pediatric Cancer Neuroblastoma Association Parent\u2019s association. In: Pediatric cancer neuroblastoma. [in Japanese] http:\/\/nbj-net.jimdofree.com\/. Accessed 24 Feb 2025"},{"key":"1566_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/cancers16030544","volume":"16","author":"A Makimoto","year":"2024","unstructured":"Makimoto A, Fujisaki H, Matsumoto K et al (2024) Retinoid therapy for neuroblastoma: historical overview, regulatory challenges, and prospects. Cancers (Basel) 16:544. https:\/\/doi.org\/10.3390\/cancers16030544","journal-title":"Cancers (Basel)"},{"key":"1566_CR24","unstructured":"Takeda Pharmaceutical Company (2025) Challenges of rare diseases in Japan. [in Japanese] https:\/\/www.takeda.co.jp\/patients\/rd-support\/wp\/. Accessed 9 Apr 2025"},{"key":"1566_CR25","unstructured":"Notification No. 1023\u20133 Ministry of Health, Labor and Welfare Pharmaceutical Evaluation Division. [in Japanese] https:\/\/www.pmda.go.jp\/files\/000273721.pdf. Accessed 3 Jul 2025"},{"key":"1566_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.clinthera.2014.01.013","volume":"36","author":"R Ahmed","year":"2014","unstructured":"Ahmed R, Duerr U, Gavenis K et al (2014) Challenges for academic investigator-initiated pediatric trials for rare diseases. Clin Ther 36:184\u2013190. https:\/\/doi.org\/10.1016\/j.clinthera.2014.01.013","journal-title":"Clin Ther"},{"key":"1566_CR27","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.2013.285873","volume":"311","author":"ML Batshaw","year":"2014","unstructured":"Batshaw ML, Groft SC, Krischer JP (2014) Research into rare diseases of childhood. JAMA 311:1729\u20131730. https:\/\/doi.org\/10.1001\/jama.2013.285873","journal-title":"JAMA"},{"key":"1566_CR28","unstructured":"Patient-Proposed Healthcare Services. [in Japanese] https:\/\/www.mhlw.go.jp\/moushideryouyou\/professional.html. Accessed 10 Jun 2025"},{"key":"1566_CR29","doi-asserted-by":"publisher","first-page":"1009432","DOI":"10.3389\/fmed.2022.1009432","volume":"9","author":"H Christiansen","year":"2022","unstructured":"Christiansen H, De Bruin ML, Hallgreen CE (2022) Mandatory requirements for pediatric drug development in the EU and the US for novel drugs-a comparative study. Front Med (Lausanne) 9:1009432. https:\/\/doi.org\/10.3389\/fmed.2022.1009432","journal-title":"Front Med (Lausanne)"},{"key":"1566_CR30","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1377\/hlthaff.2020.00198","volume":"39","author":"M Carmack","year":"2020","unstructured":"Carmack M, Hwang T, Bourgeois FT (2020) Pediatric drug policies supporting safe and effective use of therapeutics in children: a systematic analysis: study examines safe and effective use of therapeutics in children. Health Aff (Millwood) 39:1799\u20131805. https:\/\/doi.org\/10.1377\/hlthaff.2020.00198","journal-title":"Health Aff (Millwood)"},{"key":"1566_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.curtheres.2018.12.001","volume":"90","author":"C Spadoni","year":"2019","unstructured":"Spadoni C (2019) Pediatric drug development: challenges and opportunities. Curr Ther Res Clin Exp 90:119\u2013122. https:\/\/doi.org\/10.1016\/j.curtheres.2018.12.001","journal-title":"Curr Ther Res Clin Exp"},{"key":"1566_CR32","unstructured":"Notification No. 1618 (Drug Approval and Licensing Authority) Pharmaceuticals and Medical Devices Agency. [in Japanese] https:\/\/www.pmda.go.jp\/files\/000274421.pdf. Accessed 14 Apr 2025"},{"key":"1566_CR33","unstructured":"Results of the Research Group under the 2024 Health and Labour Sciences Special Research Project \u201cInvestigation of Drug Loss Reality and Construction of Solutions\u201d. [In Japanese] https:\/\/www.mhlw.go.jp\/stf\/newpage_56135.html. Accessed 10 Jun 2025"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01566-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01566-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01566-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:03:05Z","timestamp":1760194985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01566-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01566-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"26 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}